Quest Partners LLC Has $661,000 Position in Artivion, Inc. (NYSE:AORT)

Quest Partners LLC raised its holdings in shares of Artivion, Inc. (NYSE:AORT) by 2,481,700.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,818 shares of the company’s stock after purchasing an additional 24,817 shares during the quarter. Quest Partners LLC owned approximately 0.06% of Artivion worth $661,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of AORT. Russell Investments Group Ltd. grew its holdings in shares of Artivion by 26.9% during the 1st quarter. Russell Investments Group Ltd. now owns 15,187 shares of the company’s stock worth $321,000 after purchasing an additional 3,217 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Artivion by 70.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 19,197 shares of the company’s stock valued at $406,000 after buying an additional 7,940 shares in the last quarter. Vanguard Group Inc. grew its position in Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after acquiring an additional 33,982 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Artivion by 7.9% in the first quarter. CANADA LIFE ASSURANCE Co now owns 34,461 shares of the company’s stock worth $729,000 after acquiring an additional 2,531 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Artivion by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after purchasing an additional 1,634 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Insider Buying and Selling at Artivion

In related news, CAO Amy Horton sold 12,430 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares in the company, valued at $3,664,912.02. This trade represents a 8.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at approximately $4,299,294.60. The trade was a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Oppenheimer raised their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Needham & Company LLC restated a “buy” rating and set a $30.00 price target on shares of Artivion in a report on Friday, September 27th. Stifel Nicolaus raised their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Finally, JMP Securities began coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $31.00.

Artivion Stock Up 0.8 %

Shares of NYSE:AORT opened at $28.27 on Friday. The business’s 50-day moving average is $26.56 and its 200-day moving average is $25.55. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $30.00. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -1,404.50 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.